Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

BACKGROUND: Erlotinib is approved for the first line treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer. Since the number of prospective studies in Caucasian patients treated in routine clinical setting is limited we conducted a multicenter, phase IV cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Markóczy, Zsolt, Sárosi, Veronika, Kudaba, Iveta, Gálffy, Gabriella, Turay, Ülkü Yilmaz, Demirkazik, Ahmet, Purkalne, Gunta, Somfay, Attila, Pápai-Székely, Zsolt, Rásó, Erzsébet, Ostoros, Gyula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970529/
https://www.ncbi.nlm.nih.gov/pubmed/29801465
http://dx.doi.org/10.1186/s12885-018-4283-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970529/
https://www.ncbi.nlm.nih.gov/pubmed/29801465
http://dx.doi.org/10.1186/s12885-018-4283-z

Ejemplares similares